Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Trial Profile

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 04 Nov 2019 Results assessing efficacy and safety of acalabrutinib versus other targeted therapies employed for the treatment of relapsed/refractory MCL published in the Clinical Therapeutics
    • 08 Oct 2019 Results published in the AstraZeneca Media Release.
    • 08 Oct 2019 According to an AstraZeneca media release, the Health Canada approves Calquence(acalabrutinib) as an oral therapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top